SCHEDULE: Vanguard Discloses 7.98% Stake in Evolent Health

The Vanguard Group reported a 7.98% beneficial ownership stake in Evolent Health Inc., holding 8,914,065 common shares as of December 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 8,914,065 shares of Evolent Health Inc. common stock.
• This ownership represents 7.98% of the class of securities.
• Vanguard holds shared voting power over 933,846 shares and shared dispositive power over 8,914,065 shares.
• An internal realignment occurred at The Vanguard Group on January 12, 2026, resulting in it no longer performing portfolio management services or administering proxy voting.
• Vanguard anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) in the future.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive for Evolent Health Inc. due to the disclosure of a substantial institutional holding by The Vanguard Group, which can signal investor confidence. The internal realignment at Vanguard is an operational matter for the reporting entity and does not directly impact Evolent's operational sentiment.

Positives

• A significant institutional investor like The Vanguard Group holding a 7.98% stake can be viewed as a vote of confidence in Evolent Health Inc.

Future Outlook

The Vanguard Group anticipates that certain subsidiaries or business divisions will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. following an internal realignment on January 12, 2026.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting.
• The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.

Industry Context

StockSavvy.ai notes that The Vanguard Group's significant stake in Evolent Health Inc. underscores continued institutional interest in the healthcare technology sector. The internal realignment at Vanguard, leading to disaggregated reporting by its subsidiaries, reflects a broader trend among large asset managers to streamline operations and potentially enhance transparency or specialization within their various investment arms.

Comparison to Industry Standards

• This filing primarily concerns beneficial ownership disclosure by a major institutional investor, The Vanguard Group, in Evolent Health Inc. It does not provide performance metrics for direct comparison to industry standards or specific comparable companies/projects. However, large institutional holdings like Vanguard's are common across well-established public companies, indicating a standard level of institutional confidence.

Stakeholder Impact

• Shareholders: The significant stake held by The Vanguard Group may provide a level of stability and confidence, as large institutional holdings often imply thorough due diligence.
• Investment Community: The disclosure provides transparency regarding a major institutional investor's position in Evolent Health Inc.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report beneficial ownership separately (on a disaggregated basis) in the future.

Key Dates

Recommendation

A Schedule 13G filing primarily discloses beneficial ownership and does not provide sufficient operational or financial data to issue a strong buy or sell recommendation. However, the substantial 7.98% stake held by The Vanguard Group, a prominent institutional investor, suggests a baseline level of confidence in Evolent Health Inc. For existing investors, this reinforces a 'hold' position, while new investors would require further fundamental analysis beyond this ownership disclosure.

Keywords

Evolent Health Inc., Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional investor, investment adviser